Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations
Company Announcements

Cue Biopharma Refocuses on Autoimmune Programs, Restructures Operations

An update from Cue Biopharma (CUE) is now available.

Cue Biopharma, Inc. has announced a strategic shift to focus on its autoimmune programs and a restructure aimed at enhancing operational efficiency, which includes a 25% workforce reduction and voluntary salary and bonus cuts by its CEO and executive officers. These changes are expected to extend the company’s financial runway into mid-2025, signaling a proactive approach to managing resources while advancing its strategic objectives in the competitive biopharmaceutical landscape.

For an in-depth examination of CUE stock, go to TipRanks’ Stock Analysis page.

Related Articles
Catie PowersCUE Upcoming Earnings Report: What to Expect?
TheFlyCue Biopharma presents ‘positive’ update from Phase 1 trials of CUE-101, CUE-102
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App